NCT02724527View on ClinicalTrials.gov

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

PHASE2UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

Cavosonstat

CFTR modulator that stabilizes CFTR

DRUG

Placebo

Matched Placebo capsule

Trial Locations (12)

10032

Columbia University, New York

15224

Children's Hospital Pittsburgh, Pittsburgh

21287

Johns Hopkins Hospital, Baltimore

43205

Nationwide Children's Hospital, Columbus

44106

Rainbow Babies and Children's Hospital - Case Medical Center, Cleveland

45229

Cincinnati Children's Hospital, Cincinnati

53792

Medical Center of Wisconsin, Madison

63110

Washington University, St Louis

80206

National Jewish Health, Denver

84132

University of Utah, Salt Lake City

97239

Oregon Health and Science University, Portland

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Nivalis Therapeutics, Inc.

INDUSTRY

NCT02724527 - Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor | Biotech Hunter | Biotech Hunter